A two-stage algorithm for designing phase I cancer clinical trials for two new molecular entities

Contemporary Clinical Trials

Volumn 31, Issue 1, 2010, Pages 105-107

  Su, Zheng ^a  

^a GENENTECH INC   (United States)

Author keywords

Clinical trial; Dose escalation; MTD; New molecular entity; Phase I; Toxicity

Indexed keywords

ALGORITHM; ARTICLE; BAYES THEOREM; CANCER RESEARCH; STATISTICAL MODEL;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BAYES THEOREM; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, INVESTIGATIONAL; HUMANS; LIKELIHOOD FUNCTIONS; MAXIMUM TOLERATED DOSE; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 73049087004     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2009.10.004     Document Type: Article

References (11)

1. Storer B. Design and analysis of phase I clinical trials. Biometrics 45 3 (1989) 925-937
2. O'Quigley J., Pepe M., and Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 46 1 (1990) 33-48
3. O'Quigley J., and Shen L. Continual reassessment method: a likelihood approach. Biometrics 52 2 (1996) 673-684
4. Goodman S.N., Zahurak M.L., and Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 14 (1995) 1149-1161
5. Piantadosi S., Fisher J.D., and Grossman S. Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother Pharmacol 41 6 (1998) 429-436
6. Bekele B.N., and Thall P.F. Dose-finding based on multiple toxicities in a soft tissue sarcoma trial. J Am Stat Assoc 99 465 (2004) 26-35
7. Jiang H., Liu Y., and Su Z. An optimazation algorithm for designing phase I cancer clincal trials. Contemp Clin Trials 29 2 (2008) 102-108
8. Garrett-Meyer E. Understanding the continual reassessment method for dose finding studies: an overview for non-statisticians. Johns Hopkins University, Dept. of Biostatistics Working Papers. Working Paper vol. 74 (2005). http://www.bepress.com/jhubiostat/paper74 http://www.bepress.com/jhubiostat/paper74
9. Kramer A., Lebecq A., and Candalh E. Continual reassessment methods in Phase I trials of the combination of two drugs in oncology. Stat Med 18 (1999) 1849-1864
10. Thall P.F., Millikan R.E., Müller P., and Lee S.J. Dose-finding with two agents in phase I oncology trials. Biometrics 59 (2003) 487-496
11. Wang K., and Ivanova A. Two-dimensional dose finding in discrete dose space. Biometrics 61 (2005) 217-222